Asked by: Dan Carden (Labour - Liverpool Walton)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether his Department plans to increase funding for research into Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
As set out in the final delivery plan, the Department has taken actions to strengthen research capacity and capability in relation to myalgic encephalomyelitis, also known as chronic fatigue syndrome (ME/CFS). The level of research funding is determined by the quantity and quality of proposals that are recommended for support through the competitive process through the National Institute for Health and Care Research (NIHR) funding committees.
The actions announced in the final delivery plan include a research showcase event, a new funding opportunity for a development award focussed on evaluating repurposed pharmaceutical interventions, and the announcement of new funded studies in health and care services, research infrastructure, and capacity-building.
We are determined to accelerate progress in the treatment and management of ME/CFS and will continue working with the ME/CFS community to identify and address barriers to research. The NIHR welcomes funding applications for research into any aspect of human health and care, including ME/CFS. Research funding is available, and applications are subject to peer review and judged in open competition, with awards made on the basis of the importance of the topic to patients and health and care services, value for money, and scientific quality.
Asked by: Dan Carden (Labour - Liverpool Walton)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, how many women in Liverpool Walton have been referred to NHS services in connection with PIP implants since 2011.
Answered by Karin Smyth - Minister of State (Department of Health and Social Care)
The Department of Health and Social Care has indicated that it will not be possible to answer this question within the usual time period. An answer is being prepared and will be provided as soon as it is available.
Asked by: Dan Carden (Labour - Liverpool Walton)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what mechanisms exist to support waste-reduction trials with NHS trusts.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
The Department and NHS England are always looking at ways of reducing waste and increasing efficiency. NHS England has had many discussions with National Health Service trusts on the reduction, elimination, and reuse of single-use polypropylene curtains, and have published best practice with regards to safe and sustainable management of healthcare waste.
In addition, the Department has published the Design for Life Roadmap, a new strategy to transition away from all avoidable single-use medical technology (medtech) products towards a functioning circular system by 2045. This means designing, procuring, and processing medtech products in a way that maximises reuse, remanufacture, and recycling, thus preserving their value for as long as possible. The document sets out a plan of 30 actions to deliver the 2045 vision, which involve:
The Design for Life Roadmap is available at the following link:
https://www.gov.uk/government/publications/design-for-life-roadmap
As part of its work, the Design for Life programme maintains a list of products where circular alternatives are already available, and, for those with the highest potential benefits, explores means to accelerate adoption across the NHS. Ward curtains are on this product list, where a dedicated group, including procurement and clinical experts, are working to explore how the adoption of reusable versions can be supported.
With regards to trials, the Design for Life programme has commissioned several pilots within NHS trusts to explore safe transitions from single-use to reusables, where the results have been published and cascaded among the NHS community. Furthermore, NHS England has developed and deployed an Innovation Portal to help document, evaluate, test, and deploy innovations in waste management across the NHS in England.
Asked by: Dan Carden (Labour - Liverpool Walton)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether his Department has had discussions with NHS trusts on the potential reuse of polypropylene ward curtains.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
The Department and NHS England are always looking at ways of reducing waste and increasing efficiency. NHS England has had many discussions with National Health Service trusts on the reduction, elimination, and reuse of single-use polypropylene curtains, and have published best practice with regards to safe and sustainable management of healthcare waste.
In addition, the Department has published the Design for Life Roadmap, a new strategy to transition away from all avoidable single-use medical technology (medtech) products towards a functioning circular system by 2045. This means designing, procuring, and processing medtech products in a way that maximises reuse, remanufacture, and recycling, thus preserving their value for as long as possible. The document sets out a plan of 30 actions to deliver the 2045 vision, which involve:
The Design for Life Roadmap is available at the following link:
https://www.gov.uk/government/publications/design-for-life-roadmap
As part of its work, the Design for Life programme maintains a list of products where circular alternatives are already available, and, for those with the highest potential benefits, explores means to accelerate adoption across the NHS. Ward curtains are on this product list, where a dedicated group, including procurement and clinical experts, are working to explore how the adoption of reusable versions can be supported.
With regards to trials, the Design for Life programme has commissioned several pilots within NHS trusts to explore safe transitions from single-use to reusables, where the results have been published and cascaded among the NHS community. Furthermore, NHS England has developed and deployed an Innovation Portal to help document, evaluate, test, and deploy innovations in waste management across the NHS in England.
Asked by: Dan Carden (Labour - Liverpool Walton)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to reduce levels of NHS waste.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
The Department and NHS England are always looking at ways of reducing waste and increasing efficiency. NHS England has had many discussions with National Health Service trusts on the reduction, elimination, and reuse of single-use polypropylene curtains, and have published best practice with regards to safe and sustainable management of healthcare waste.
In addition, the Department has published the Design for Life Roadmap, a new strategy to transition away from all avoidable single-use medical technology (medtech) products towards a functioning circular system by 2045. This means designing, procuring, and processing medtech products in a way that maximises reuse, remanufacture, and recycling, thus preserving their value for as long as possible. The document sets out a plan of 30 actions to deliver the 2045 vision, which involve:
The Design for Life Roadmap is available at the following link:
https://www.gov.uk/government/publications/design-for-life-roadmap
As part of its work, the Design for Life programme maintains a list of products where circular alternatives are already available, and, for those with the highest potential benefits, explores means to accelerate adoption across the NHS. Ward curtains are on this product list, where a dedicated group, including procurement and clinical experts, are working to explore how the adoption of reusable versions can be supported.
With regards to trials, the Design for Life programme has commissioned several pilots within NHS trusts to explore safe transitions from single-use to reusables, where the results have been published and cascaded among the NHS community. Furthermore, NHS England has developed and deployed an Innovation Portal to help document, evaluate, test, and deploy innovations in waste management across the NHS in England.
Asked by: Dan Carden (Labour - Liverpool Walton)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 30 October to Question 84069 on Physician Assistants, if his Department will set out a timeline for reviewing existing guidance for employers.
Answered by Karin Smyth - Minister of State (Department of Health and Social Care)
NHS England is currently considering next steps for supporting the wider National Health Service and relevant stakeholders to implement the recommendations of the Leng Review, starting with those focused on patient safety, as requested by the Government.
We will continue to work closely and collaboratively with partners across the NHS, the clinical professions, and their representative bodies so that patients receive safe, effective, and compassionate care in line with the relevant legal and clinical processes. As part of this, NHS England will be working with NHS Employers over the coming months, supported by colleagues in the regions, to consider what guidance and support can be provided to the system to implement those recommendations related to the employment of physician assistants.
As further information to support implementation of the recommendations is available, it will be published at the following link:
Asked by: Dan Carden (Labour - Liverpool Walton)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what recent assessment his Department has made of the efficacy of the regulatory framework for the health and wellness sector.
Answered by Karin Smyth - Minister of State (Department of Health and Social Care)
The Government has not made a recent assessment of the efficacy of the regulatory framework for the health and wellness sector.
Asked by: Dan Carden (Labour - Liverpool Walton)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to improve treatment of phenylketonuria.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The Government is committed to improving the lives of those living with rare diseases, such as phenylketonuria, through the UK Rare Diseases Framework.
The fourth priority of the Framework is improved access to specialist care, treatment and drugs. In February 2025, the England Rare Diseases Action Plan 2025 was published, including progress made under this priority:
- Meeting to discuss the effectiveness of early access pathways for rare disease therapies;
- Launching a review of the National Institute for Health and Care Excellence highly specialised technology programme for evaluating rare disease treatments; and
- Introducing two new actions on reforming clinical trial regulations; and developing an operational framework for individualised therapies in the National Health Service.
The NHS England Health A to Z page contains information about symptoms, medicines, tests and treatments, including what to do and when to get help. There is an NHS England webpage on phenylketonuria, which is available at the following link: https://www.nhs.uk/conditions/phenylketonuria/.
Since 2021, the treatment sapropterin has been available to all eligible people with phenylketonuria. Clinical trials suggest that around four in 10 people may benefit from sapropterin, improving their quality of life significantly and reducing restrictions on the food they can eat.
Asked by: Dan Carden (Labour - Liverpool Walton)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to improve (a) diagnosis and (b) treatment for Paediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections.
Answered by Stephen Kinnock - Minister of State (Department of Health and Social Care)
The Department recognises the importance of raising awareness of conditions such as paediatric acute-onset neuropsychiatric syndrome (PANS) and paediatric autoimmune neuropsychiatric disorder associated with streptococcus (PANDAS) among healthcare professionals, and improving the health and care system for the people living with them.
The National Institute for Health and Care Excellence (NICE) is the independent, expert body that develops evidence-based guidelines for the National Health Service on best practice. While the NICE currently has no plans to issue guidance on PANS and PANDAS, should the evidence base develop further, we would look to the NICE to update clinical policy.
In the meantime, integrated care systems are responsible for planning care for their populations’ conditions, and clinicians will want to take account of any new research and developments in guidance, such as those being overseen by the PANS PANDAS Steering Group, to ensure that they can continue to provide high quality care to their patients.
Asked by: Dan Carden (Labour - Liverpool Walton)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to improve diagnosis times for young people with cancer.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The Department is committed to getting the National Health Service diagnosing cancer earlier and treating it faster so that more patients survive this horrible set of diseases, including children and young people. To achieve this, the NHS has delivered an extra 40,000 operations, scans, and appointments each week as the first step to ensuring early diagnosis and faster treatment.
On 4 February 2025, the Department relaunched the Children and Young People Cancer Taskforce to identify tangible ways to improve outcomes and experiences for children and young people with cancer.
The forthcoming National Cancer Plan will include further details on how we will improve outcomes for cancer patients, including for children and young people with cancer, and will highlight how we aim to improve diagnosis rates for people across England.